Fishman Jay A Ltd. MI Grows Stock Position in Stryker Co. (NYSE:SYK)

Fishman Jay A Ltd. MI boosted its holdings in Stryker Co. (NYSE:SYK) by 0.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 80,627 shares of the medical technology company’s stock after acquiring an additional 50 shares during the period. Stryker accounts for about 2.7% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 11th largest position. Fishman Jay A Ltd. MI’s holdings in Stryker were worth $29,030,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Parnassus Investments LLC acquired a new stake in shares of Stryker in the third quarter valued at approximately $762,798,000. International Assets Investment Management LLC lifted its stake in Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock valued at $308,433,000 after buying an additional 852,496 shares in the last quarter. RTW Investments LP purchased a new position in Stryker during the third quarter worth $143,392,000. State Street Corp increased its position in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after buying an additional 316,404 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Stryker by 3.0% in the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after acquiring an additional 215,782 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 0.5 %

SYK opened at $390.52 on Wednesday. The company has a market cap of $148.88 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a 50 day moving average price of $377.28 and a 200 day moving average price of $365.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 earnings per share. Sell-side analysts expect that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent research reports. Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Citigroup upped their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI lifted their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $420.68.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.